세계의 안지오텐신 전환효소(ACE) 억제제 시장 : 약제 유형별, 질환 유형별, 투약 형태별, 유통 채널별, 환자 속성별 - 예측(2025-2030년)

The Angiotensin Converting Enzyme Inhibitors Market was valued at USD 3.70 billion in 2023, expected to reach USD 3.92 billion in 2024, and is projected to grow at a CAGR of 6.23%, to USD 5.65 billion by 2030.

Angiotensin Converting Enzyme (ACE) Inhibitors are a class of medications primarily used to treat hypertension and congestive heart failure. They work by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. The necessity of ACE inhibitors stems from the global prevalence of hypertension and cardiovascular diseases, positioning these drugs as crucial in managing cardiovascular health. Their application extends beyond hypertension to include diabetic nephropathy and post-myocardial infarction treatment, enhancing their significance in therapeutic regimens. The primary end-users include hospitals, clinics, and individual patients, prompting consistent demand across diverse healthcare settings. Key factors driving market growth include the rising incidence of lifestyle-related health conditions and increasing awareness about cardiovascular health. Additionally, the aging global population underpinning a higher prevalence of chronic cardiovascular conditions propels market demand. However, the market faces limitations such as patent expirations leading to generic drug competition, and side effects like cough and angioedema, which may limit patient compliance. Regulatory hurdles and the need for rigorous clinical trials further challenge market expansion. Nonetheless, opportunities exist in developing innovative formulation techniques to improve drug delivery and patient adherence, such as release profiles and combination therapies with other antihypertensives. Monitoring emerging markets where healthcare infrastructure is improving also offers potential growth avenues. To capitalize on these opportunities, companies should focus on strategic partnerships for expanded distribution, invest in research and development for newer, more efficient drug formulations, and explore digital health technologies for remote patient monitoring and adherence tracking. The market is inherently competitive, necessitating constant innovation and adaptation to regulatory environments and patient needs, thus maintaining relevance and competitive advantage in the global market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
  • Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
  • Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
  • Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
• Market Restraints
  • Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
  • Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
• Market Opportunities
  • Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
  • Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
  • Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
• Market Challenges
  • Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
  • Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Angiotensin Converting Enzyme Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angiotensin Converting Enzyme Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angiotensin Converting Enzyme Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angiotensin Converting Enzyme Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angiotensin Converting Enzyme Inhibitors Market

A detailed market share analysis in the Angiotensin Converting Enzyme Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angiotensin Converting Enzyme Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angiotensin Converting Enzyme Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angiotensin Converting Enzyme Inhibitors Market

A strategic analysis of the Angiotensin Converting Enzyme Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angiotensin Converting Enzyme Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Angiotensin Converting Enzyme Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Non-Specific ACE Inhibitors and Specific ACE Inhibitors.
• Based on Disease Type, market is studied across Heart Diseases, Hypertension, and Kidney Diseases. The Heart Diseases is further studied across Chronic Heart Failure and Coronary Artery Disease. The Hypertension is further studied across Primary Hypertension and Secondary Hypertension. The Kidney Diseases is further studied across Chronic Kidney Diseases and Diabetic Nephropathy.
• Based on Dosage Form, market is studied across Capsules, Injectable, and Tablets.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
    • 5.1.1.2. Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
    • 5.1.1.3. Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
    • 5.1.1.4. Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
  • 5.1.2. Restraints
    • 5.1.2.1. Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
    • 5.1.2.2. Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
  • 5.1.3. Opportunities
    • 5.1.3.1. Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
    • 5.1.3.2. Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
    • 5.1.3.3. Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
  • 5.1.4. Challenges
    • 5.1.4.1. Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
    • 5.1.4.2. Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Angiotensin Converting Enzyme Inhibitors Market, by Drug Type

• 6.1. Introduction
• 6.2. Non-Specific ACE Inhibitors
• 6.3. Specific ACE Inhibitors

7. Angiotensin Converting Enzyme Inhibitors Market, by Disease Type

• 7.1. Introduction
• 7.2. Heart Diseases
  • 7.2.1. Chronic Heart Failure
  • 7.2.2. Coronary Artery Disease
• 7.3. Hypertension
  • 7.3.1. Primary Hypertension
  • 7.3.2. Secondary Hypertension
• 7.4. Kidney Diseases
  • 7.4.1. Chronic Kidney Diseases
  • 7.4.2. Diabetic Nephropathy

8. Angiotensin Converting Enzyme Inhibitors Market, by Dosage Form

• 8.1. Introduction
• 8.2. Capsules
• 8.3. Injectable
• 8.4. Tablets

9. Angiotensin Converting Enzyme Inhibitors Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Angiotensin Converting Enzyme Inhibitors Market, by Patient Demographics

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Americas Angiotensin Converting Enzyme Inhibitors Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Boehringer Ingelheim GmbH
• 7. Bristol-Myers Squibb Company
• 8. Daiichi Sankyo Company, Limited
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline plc
• 12. Johnson & Johnson
• 13. Merck & Co., Inc.
• 14. Mylan N.V.
• 15. Novartis AG
• 16. Pfizer Inc.
• 17. Roche Holding AG
• 18. Sanofi S.A.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.